HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Askoxylakis, V. Articles by Haberkorn, U. Search for Related Content PubMed PubMed Citation Articles by Askoxylakis, V. Articles by Haberkorn, U.

Characterization and Development of a Peptide (p160) with Affinity for Neuroblastoma Cells

¹ Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ) and University of Heidelberg, Heidelberg, Germany; ² Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany; ³ Institute for Pathology, University of Heidelberg, Heidelberg, Germany; ⁴ Institute for Biological Sciences, National Research Council, Ottawa, Canada; ⁵ Department of Tumour Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany; and ⁶ Department of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany

Correspondence: For correspondence or reprints contact: Uwe Haberkorn, MD, Department of Nuclear Medicine, University of Heidelberg, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany. E-mail: uwe_haberkorn{at}med.uni-heidelberg.de

Drug-targeting strategies can increase the efficacy and reduce the side effects and toxicity of conventional chemotherapy or may lead to new radiolabeled molecules useful for diagnosis and therapy. To identify and characterize new carrier molecules, we evaluated a peptide that had been identified by phage display technology. Methods: The peptide p160 (VPWMEPAYQRFL) was prepared by solid-phase peptide synthesis and radiolabeled with ¹²⁵I or ¹³¹I. The radiolabeled peptide and derivatives of it were used to study binding and internalization in vitro and to assess their distribution in tumor-bearing mice. Results: Cell-binding assays on the human neuroblastoma cell line WAC 2 indicated the affinity and specificity of ¹²⁵I-labeled p160 toward neuroblastoma cells. Binding of the ¹²⁵I-labeled p160 was inhibited up to 95% by the unlabeled peptide. Furthermore, 50% of the total bound activity was internalized into the neuroblastoma cells. Biodistribution studies on nude mice showed a higher tracer accumulation in tumors than in most organs. Perfusion of the animals reduced uptake in all tissues, whereas tumor uptake remained constant. Fluorescence-activated cell-sorting studies with fluorescein isothiocyanate–labeled p160 demonstrated an increased fluorescence signal. Investigation of the binding properties of the fragments p160-8-1, p160-8-2, and p160-8-3 indicated that the sequence EPAYQR might be of significance for the binding of p160. Conclusion: These data indicate that the p160 peptide is an attractive candidate for the development of a neuroblastoma-specific vector that can be used for drug targeting or radiopeptide-based diagnosis and therapy.

Key Words: peptide • tumor affinity • neuroblastoma

This article has been cited by other articles:

				W. Mier, S. Zitzmann, S. Kramer, J. Reed, E.-M. Knapp, A. Altmann, M. Eisenhut, and U. Haberkorn Influence of Chelate Conjugation on a Newly Identified Tumor-Targeting Peptide J. Nucl. Med., September 1, 2007; 48(9): 1545 - 1552. [Abstract] [Full Text] [PDF]